These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 19153548

  • 1. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E, Chlebna-Sokół D.
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [Abstract] [Full Text] [Related]

  • 2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C, Rauch F, Travers R, Glorieux FH.
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [Abstract] [Full Text] [Related]

  • 3. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O, Tamasanu RC, Mang N, Mozos I, Brad GF.
    Drug Des Devel Ther; 2017 Mar; 11():2507-2515. PubMed ID: 28894358
    [Abstract] [Full Text] [Related]

  • 4. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA, Ford L, McClintock C, Peacock M.
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [Abstract] [Full Text] [Related]

  • 5. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E, Jorulf H, Söderhäll S.
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [Abstract] [Full Text] [Related]

  • 6. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I, Iqbal F, Lone SW, Ibrahim M, Khan YN, Raza J.
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [Abstract] [Full Text] [Related]

  • 7. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S, Tavakkoli S.
    J Pediatr Endocrinol Metab; 2010 Sep; 23(1-2):73-80. PubMed ID: 20432809
    [Abstract] [Full Text] [Related]

  • 8. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F.
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [Abstract] [Full Text] [Related]

  • 9. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E.
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [Abstract] [Full Text] [Related]

  • 10. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS, Glorieux FH, Rauch F.
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [Abstract] [Full Text] [Related]

  • 11. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [Abstract] [Full Text] [Related]

  • 12. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T, Bompadre V, White KK.
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [Abstract] [Full Text] [Related]

  • 14. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T, Turan S, Guran T, Bereket A.
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [Abstract] [Full Text] [Related]

  • 15. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA, Peacock M.
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [Abstract] [Full Text] [Related]

  • 16. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [Abstract] [Full Text] [Related]

  • 17. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R.
    N Engl J Med; 1998 Oct 01; 339(14):947-52. PubMed ID: 9753709
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
    Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.
    Joint Bone Spine; 2005 Jul 01; 72(4):313-8. PubMed ID: 16038843
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA, Aglan MS, Ibrahim MM, Elnashar M, El Banna RA, Temtamy SA.
    Osteoporos Int; 2016 Jan 01; 27(1):81-92. PubMed ID: 26138583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.